FY2018 EPS Estimates for Johnson & Johnson Cut by Analyst (JNJ)
Johnson & Johnson (NYSE:JNJ) – Analysts at Jefferies Group cut their FY2018 EPS estimates for Johnson & Johnson in a research report issued on Thursday. Jefferies Group analyst J. Holford now anticipates that the brokerage will post earnings of $7.16 per share for the year, down from their prior estimate of $7.30. Jefferies Group has a “Hold” rating and a $115.00 price objective on the stock. Jefferies Group also issued estimates for Johnson & Johnson’s FY2019 earnings at $7.80 EPS and FY2020 earnings at $8.52 EPS.
A number of other analysts have also recently commented on the company. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price target for the company in a research report on Monday, August 22nd. Barclays PLC reissued an “overweight” rating and issued a $125.00 price objective (up previously from $120.00) on shares of Johnson & Johnson in a report on Sunday, July 10th. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price objective for the company in a report on Friday, August 5th. BTIG Research reissued a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, September 7th. Finally, Credit Suisse Group AG reissued a “neutral” rating and issued a $123.00 price objective on shares of Johnson & Johnson in a report on Monday, September 19th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $120.20.
Johnson & Johnson (NYSE:JNJ) opened at 117.56 on Monday. The company’s 50-day moving average price is $118.72 and its 200-day moving average price is $117.37. Johnson & Johnson has a 52 week low of $94.28 and a 52 week high of $126.07. The company has a market capitalization of $321.63 billion, a price-to-earnings ratio of 21.91 and a beta of 0.62.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/17/fy2018-eps-estimates-for-johnson-johnson-cut-by-analyst-jnj.html
In other Johnson & Johnson news, VP Dominic J. Caruso sold 41,146 shares of the company’s stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the transaction, the vice president now directly owns 157,819 shares in the company, valued at $19,728,953.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Ronald A. Kapusta sold 2,935 shares of the company’s stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the transaction, the chief accounting officer now owns 28,660 shares in the company, valued at $3,582,786.60. The disclosure for this sale can be found here. 0.11% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Americafirst Capital Management LLC purchased a new position in Johnson & Johnson during the second quarter worth approximately $101,000. Tuttle Tactical Management LLC purchased a new position in Johnson & Johnson during the second quarter worth approximately $103,000. Lenox Wealth Management Inc. boosted its position in Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock worth $118,000 after buying an additional 190 shares during the period. Thomas J. Herzfeld Advisors Inc. boosted its position in Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock worth $122,000 after buying an additional 690 shares during the period. Finally, NCM Capital Management Group Inc. purchased a new position in Johnson & Johnson during the second quarter worth approximately $127,000. Institutional investors own 65.32% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.